Skip to main content

Miguel Del Campo Casanelles

Institutions of which they are part

Head of group
Genetics Medicine
Vall Hebron Institut de Recerca

Miguel Del Campo Casanelles

Institutions of which they are part

Head of group
Genetics Medicine
Vall Hebron Institut de Recerca

Research lines

Prenatal genetics


IP: Carlota Rodó Rodríguez, Maria Ángeles Sánchez Durán, Miguel Del Campo Casanelles, Ma Irene Valenzuela Palafoll

Projects

Estudio multidimensional del espectro de los trastornos relacionados con la exposición prenatal al alcohol

IP: Miguel Del Campo Casanelles
Collaborators: Núria Gómez Barros, Carlos Jacas Escarcellé, Susana Boronat Guerero, Anna Maria Cueto Gonzalez
Funding agency: Instituto de Salud Carlos III
Funding: 99220
Reference: PI12/02289
Duration: 01/01/2013 - 31/12/2015

Eficacia y seguridad de losartan vs atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con síndrome de Marfan LOAT

IP: -
Collaborators: Miguel Del Campo Casanelles, Jose Fernando Rodríguez Palomares
Funding agency: Instituto de Salud Carlos III
Funding: 249865
Reference: EC07/90396
Duration: 01/11/2007 - 31/10/2012

Evaluación de la eficacia y seguridad de Losartán en la reducción del estrés oxidativo y la disminución de la Tensión Arterial (TA) en pacientes con síndrome de Williams (SW) y dos o más copias del gen NCF1

IP: Miguel Del Campo Casanelles
Collaborators: Pedro Betrian Blasco, Luis Enrique Lara Moctezuma
Funding agency: Instituto de Salud Carlos III
Funding: 161305.1
Reference: EC07/90123
Duration: 01/11/2007 - 31/12/2010

Rare Disease Portal RD-PORTAL Grant No 2006119 Funding agency: Public Health Executive Agency (PHEA)

IP: Miguel Del Campo Casanelles
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 125392.23
Reference: ORPHANET-2006119
Duration: 01/04/2007 - 31/03/2010

Related news

Over the course of one week, it will host in-person assessments for 35 families to better understand the progression of the disease and contribute to the development of new therapies.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

Related professionals

Maria Isabel  Benitez  Carabante

Maria Isabel Benitez Carabante

Research technician
Childhood Cancer and Blood Disorders
Read more
Farnaz Faninam

Farnaz Faninam

Predoctoral researcher
Liver Diseases
Read more
Chiara Piccinini

Chiara Piccinini

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Jaume Sastre Garriga

Jaume Sastre Garriga

Main researcher
Neuroradiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.